Panorama of Celltrion headquarters. (Photo=Celltrion)

 

[Alpha Biz= Reporter Kim Minyoung] On the 22nd, Samsung Securities evaluated the healthcare sector, expressing expectations for both performance improvement and momentum in new drug research and development (R&D). They designated Celltrion as the top-pick stock in the biopharmaceutical field.

According to Samsung Securities, "Celltrion is expected to gradually improve its cost of goods sold (COGS) using the weighted average cost method starting from the second quarter," adding, "In the second half of the year, there is an expected leverage effect from the expansion of prescription for Jempera (Inflectra)."

However, regarding Samsung Biologics, they mentioned, "While stable earnings growth may alleviate valuation concerns, it may be difficult to upgrade the valuation rating based solely on the current growth story," and added, "After the introduction of the U.S. government's biodefense law, there have been many inquiries about contracts, but there is no significant increase in confirmed contracts to justify an upward revision of estimated factory operating rates."

 

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]